Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Filtros aplicados

Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
Eur. j. anat ; 23(5): 325-332, sept. 2019. ilus, tab
Artigo em Inglês | IBECS | ID: ibc-183862

RESUMO

Liver ischemia reperfusion is induced during surgical procedures like liver transplantation and resection. Multiple mechanisms have been postulated to liver damage following liver ischemia reperfusion injury, such as oxidative stress and inflammatory reactions. The present study declares the possible mechanism of tadalafil, toward modulating the inflammatory response. Forty-eight rats were divided into 4 groups as follows; Sham group subjected to midline laparotomy only. Tadalafil group administered Tadalafil 10 mg/kg intraperitoneal 45 min before sham operation. I/R (Ischemiareperfusion) group, rats undergo 60 min of hepatic ischemia followed by 60 min of reperfusion. Tadalafil + I/R group rats undergo a similar pattern of I/ R after the treatment with Tadalafil 10 mg/kg, 45 min before ischemia. At the end of the reperfusion, the blood samples were collected for estimation of biochemical markers including liver enzymes using colorimetric assay method and serum: TNF-α (tumor necrosis factor-α), IL-6 (interleukin 6) levels, ICAM- 1 (Intercellular Adhesion Molecule-1) were measured. Tissues were evaluated by semiquantitative and morphometrical approaches. Tadalafil succeeded in restoring normal levels of liver enzymes and ameliorating the oxidative stress as evidenced by decreasing MDA and restoring reduced glutathione levels in liver tissue homogenate. Also, Tadalafil exhibits anti-inflammatory effects, as it significantly decreased the levels of TNF-α, IL6 and ICAM-1. The findings are supported by BCL-2, TNF-α immunomarkers. It is concluded that modulation of the inflammatory response might be one of the mechanisms of Tadalafil-mediated hepatoprotection, so it is recommended as an adjuvant therapy in liver surgery


No disponible


Assuntos
Animais , Ratos , Traumatismo por Reperfusão/veterinária , Estresse Oxidativo , Transplante de Fígado/veterinária , Apoptose/efeitos dos fármacos , Fator de Necrose Tumoral alfa , Tadalafila/administração & dosagem , Fígado/anatomia & histologia , Fígado/enzimologia , Injeções Intraperitoneais/veterinária , Imuno-Histoquímica
2.
Arch. esp. urol. (Ed. impr.) ; 72(7): 670-675, sept. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-187853

RESUMO

Objetivos: Investigar la eficacia de tadalafilo 5 mg en pacientes con síntomas del tracto urinario inferior (STUI) tras fallo de los alfabloqueantes. Pacientes y métodos: Treinta y tres pacientes fueron incluidos. Se obtuvo consentimiento informado en todos los casos tras explicarles la eficacia del tadalafilo 5 mg en el tratamiento de los STUI. Antes de iniciar el tratamiento se descartaron cáncer de próstata e infección urinaria. Se evaluaron los valores de los cuestionarios IPSS, IIEF-5 y el Q max antes del tratamiento y al mes del tratamiento. Las diferencias entre los grupos se evaluaron utilizando el método de Wilcoxon. Resultados: Después de un mes con tadalafilo 5 mg, el IPSS disminuyó, y el IIEF-5 y el Q max aumentaron. Las diferencias fueron estadísticamente significativas. Conclusiones: Se ha visto que el tadalafilo 5 mg una vez al día es eficaz en el tratamiento de los STUI/HBP en pacientes con fallo previo del tratamiento con alfabloqueantes


Objectives: To investigate the efficacy of tadalafil 5mg in patients with lower urinary tract symptoms who failed alpha blocker treatment. Patients and mehods: Twenty-three patients were included. Patient consent was obtained after explaining the efficacy of tadalafil 5mg in lower urinary tract symptoms. Before initiating tadalafil 5mg treatment, prostate cancer and urinary tract infection in the patients were eliminated. IPSS, IIEF-5 and Qmax values were assessed before and one month after tadalafil 5mg treatment. Difference between two assessments was evaluated by the Wilcoxon method. RESULTS: After 1 month of Tadalafil 5mg treatment, IPSS decreased and IIEF-5 and Qmax increased. The difference between two assessments were statistically significant. Conclusion: Tadalafil 5mg once daily in the treatment of BPH/LUTS is found to be successful in patients who failed previous alpha blocker treatment


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Idoso , Sintomas do Trato Urinário Inferior/tratamento farmacológico , Inibidores da Fosfodiesterase 5/uso terapêutico , Tadalafila/uso terapêutico , Disfunção Erétil , Hiperplasia Prostática , Resultado do Tratamento
3.
Rev. int. androl. (Internet) ; 16(1): 15-19, ene.-mar. 2018. ilus
Artigo em Espanhol | IBECS | ID: ibc-170575

RESUMO

Objetivo. Evaluar la utilidad del tadalafilo en el tratamiento de la disfunción eréctil a consecuencia de una lesión uretral posterior. Material y métodos. Estudio retrospectivo que incluyó pacientes con lesión uretral posterior a consecuencia de fractura de pelvis, tratados en primera instancia mediante realineamiento uretral de urgencia y posteriormente uretroplastia término-terminal entre las 8-10 semanas posteriores al trauma. Para evaluar el grado de disfunción eréctil previa y postratamiento con tadalafilo se aplicó el cuestionario Índice Internacional de Función Eréctil (IIEF-5). Se realizó la prueba estadística de rangos de Willcoxon y estadística descriptiva. Resultados. Se incluyeron 8 pacientes en este estudio, los cuales tuvieron una media de edad de los 32,5 años. La escala IIEF previa al tratamiento con tadalafilo estuvo en promedio de 8,5puntos y tuvo un aumento postratamiento de 12,36 puntos, con una valor de p=0,011. Discusión Los 8 pacientes incluidos mostraron disfunción eréctil al momento de la evaluación IIEF, esto debido al realineamiento uretral de urgencia y derivada del trauma ocasionado por la fractura de pelvis. El tratamiento con inhibidores de la 5-fosfodiesterasa (iPDE5) es el de primera línea en pacientes con disfunción eréctil debido a que es eficiente, no invasivo y bien tolerado. En este estudio encontramos resultados que indican buena respuesta a este tratamiento en 7 de los 8 pacientes (87,5%). Solo un paciente no mostró mejoría con el tratamiento, sobresaliendo la presencia de factores de riesgo, como la edad (65 años), el tabaquismo y la hipertensión arterial. Conclusión. Se rehabilitó el 87,5% de los pacientes con lesión uretral medicados con tadalafilo (AU)


Objective. To evaluate the tadalafil effect in the treatment of erectile dysfunction as a consequence of posterior urethral injury. Material and methods. This is a retrospective study that included patients with posterior urethral injury caused by previous pelvic fracture; our patients received emergency urethral alignment and urethroplasty between 8 to 10 weeks after trauma. To assess the degree of erectile dysfunction pre- and post-treatment, we applied the questionnaire of International Index of Erectile Function (IIEF-5). Statistics Wilcoxon test and descriptive statistics were performed. Results. Eight patients were included in this study, with an average age of 32.5 years; the IIEF scale prior to treatment was on average 8.5 points and increased to 12.36 points with a value of P=.011. Discussion. These eight patients showed erectile dysfunction at the time of IIEF assessment, this due to emergency urethral realignment arising from the trauma caused by pelvic fracture. Treatment with inhibitors of 5-phosphodiesterase (iPDE5) is the first-line treatment in patients with erectile dysfunction because it is efficient, non-invasive and well tolerated. In this study we found results indicating good response to this treatment in 7 out of the 8 patients (87.5%). Only one patient showed no improvement after treatment, due to the presence of risk factors such as age (65 years), tobacco use, and high blood pressure. Conclusion. The 87.5% of patients with urethral injury medicated with tadalafil were rehabilitated (AU)


Assuntos
Humanos , Tadalafila/farmacocinética , Fraturas Ósseas/complicações , Disfunção Erétil/tratamento farmacológico , Uretra/lesões , Pelve/lesões , Resultado do Tratamento , Incontinência Urinária/epidemiologia , Estudos Retrospectivos , Citrato de Sildenafila/farmacocinética
4.
Rev. int. androl. (Internet) ; 16(1): 28-33, ene.-mar. 2018. tab
Artigo em Espanhol | IBECS | ID: ibc-170577

RESUMO

Actualmente existe un debate acerca del uso continuado de los inhibidores de la fosfodiesterasa 5 en el tratamiento de la disfunción eréctil. Varios estudios apoyan el beneficio que, incluso a bajas dosis, esta estrategia terapéutica tiene sobre la función eréctil -incluso en pacientes considerados difíciles de tratar-, y sobre la espontaneidad y naturalidad de las relaciones sexuales. También ha demostrado además ser bien tolerados y seguros. Más allá de la inhibición de la fosfodiesterasa 5, el efecto sobre la función eréctil parece basarse en la mejora de la función endotelial y de la oxigenación del área vascular peneana resultado del incremento del número de erecciones, restando así importancia a la farmacocinética. Aunque la evidencia es limitada, este nuevo escenario abre nuevas oportunidades en el tratamiento de pacientes para los que el tratamiento a demanda no es efectivo o apropiado, y podría favorecer la espontaneidad de la vida sexual (AU)


At present, there is debate regarding the continuous use of phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Cumulative evidence supports the benefit, even at low doses, thatcontinuous treatment has on erectile function -even in difficult-to-treat patients-, and on the spontaneity and naturalness of sexual relationships. Safety and tolerability have also proven to be good. Beyond phosphodiesterase 5 inhibition, the effect of continuous treatment of erectile function appears to be based on improvement of endothelial function and oxygenation of the penile vascular bed as a result of the increased number of erections, hence playing down the importance of pharmacokinetics. Although evidence is still limited, this new scenario opens new paths for the treatment of erectile dysfunction patients in whom on-demand treatments are not effective or deemed appropriate, and would benefit the spontaneity of sexual life (AU)


Assuntos
Humanos , Masculino , Disfunção Erétil/tratamento farmacológico , Inibidores da Fosfodiesterase 5/administração & dosagem , Ereção Peniana , Tempo/análise , Tadalafila/farmacocinética , Tolerância a Medicamentos , Dicloridrato de Vardenafila/farmacocinética , Citrato de Sildenafila/farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA